Esophageal Cancer

Squamous cell carcinoma vs. adenocarcinoma, Barrett's esophagus surveillance, dysphagia presentation, and trimodality therapy

Key Points

• Esophageal cancer has two main histologic types: squamous cell carcinoma (SCC, upper/mid esophagus, globally more common) and adenocarcinoma (distal esophagus/GEJ, rising incidence in Western countries).
• Barrett's esophagus — columnar metaplasia of the distal esophagus from chronic GERD — is the major precursor to esophageal adenocarcinoma.
• Dysphagia (initially to solids, progressing to liquids) is the cardinal symptom; most patients present with locally advanced or metastatic disease.
• ~17,430 new cases and ~16,120 deaths projected in the US in 2024 — a near 1:1 incidence-to-mortality ratio reflecting late-stage presentation.
• Trimodality therapy (neoadjuvant chemoradiation → surgery, CROSS regimen) is the standard for resectable locally advanced esophageal cancer.
• Nivolumab adjuvant therapy after trimodality treatment significantly improves DFS in patients with residual disease (CheckMate-577).
• First-line metastatic esophageal cancer: nivolumab or pembrolizumab + chemotherapy represents the current standard based on CPS/PD-L1 status.

Epidemiology & Incidence

Esophageal cancer is the seventh most common cancer globally and sixth most common cause of cancer death worldwide, with approximately 604,000 new cases and 544,000 deaths annually. Geographic variation is striking: the "esophageal cancer belt" from northern Iran through central Asia to northern China has extremely high SCC rates (up to 100× the Western rate). In the United States, ~17,430 new cases and ~16,120 deaths were projected in 2024 — the near 1:1 incidence-to-mortality ratio underscores the lethality of this cancer. The two histologic subtypes have dramatically different geographic,…

Genetic Predispositions & Risk Factors

Risk factors differ substantially by histologic type: Squamous cell carcinoma: • Tobacco smoking: 5–10× increased risk; synergistic with alcohol • Heavy alcohol use: Dose-dependent; ethanol and acetaldehyde are direct carcinogens • Achalasia: ~15–16× elevated SCC risk from chronic mucosal irritation by retained food/secretions • Tylosis (palmoplantar keratoderma): RHBDF2 germline mutations; near-100% lifetime risk of esophageal SCC — rare but important hereditary syndrome • Hot beverage consumption: Traditional drinking of very hot tea (>65°C) is classified as a probable carcinogen by IARC •…

Clinical Presentation

The hallmark symptom of esophageal cancer is progressive dysphagia — and its insidious onset explains why most patients present with advanced disease: • Progressive dysphagia: The most common and characteristic symptom (~90% of patients at diagnosis). Classically begins with difficulty swallowing solids (meat, bread), then progresses over weeks to months to soft foods and eventually liquids. By the time dysphagia to liquids occurs, the esophageal lumen is typically narrowed to 50% of patients at diagnosis; caused by reduced oral intake and cancer-related cachexia. Weight loss >10% body…

Staging & Treatment

Staging: AJCC 8th edition TNM (with separate staging tables for SCC and adenocarcinoma, reflecting their different prognoses at equivalent T/N stages). Workup: Upper endoscopy with biopsy, CT chest/abdomen/pelvis, PET/CT (identifies occult M1 disease in ~15–20% deemed resectable by CT alone), EUS (best for T and regional N staging in non-metastatic disease), bronchoscopy for upper/mid esophageal tumors to rule out airway invasion. Biomarkers: HER2 (IHC/FISH) for GEJ/esophageal adenocarcinoma (~15–20% HER2+); PD-L1 CPS (guides checkpoint inhibitor use); MSI/MMR; TMB. Early-stage (T1a):…